RFK Jr. taps allies, COVID vaccine critics
Digest more
After federal health officials made abrupt changes to US Covid-19 vaccine recommendations for pregnant women last month, there’s new confusion and uncertainty about who can get the shots — and some reports that patients were turned away when they tried to get vaccinated.
In recent years COVID shots joined flu shots as an annual offering at most neighborhood pharmacies. But the current administration has thrown that into uncertainty
1hon MSN
COVID-19 patients who are vaccinated -- and were hospitalized with reduced kidney function -- had better outcomes than unvaccinated patients, a new study finds.
U.S. Health Secretary Robert F. Kennedy Jr. on Wednesday named eight new vaccine policy advisers to replace the panel that he abruptly dismissed earlier this week. They include a scientist who researched mRNA vaccine technology and became a conservative darling for his criticisms of COVID-19 vaccines,
The FDA's approval was based on a study of 11,400 people age 12 and older that compared the new low-dose vaccine with Moderna's existing vaccine. It found the new vaccine was safe and was at least as effective - and more by some measures - than the original shot, the company said.
The CDC's recommendation for the COVID-19 vaccine is changing for pregnant women and children. Here's what Kentucky experts have to say.
Now that Covid vaccines are no longer recommended for healthy children and pregnant people, boosters could be a lot more expensive this fall. Here’s why.
Vaccinated patients hospitalized with COVID-19 who developed acute kidney injury had better outcomes than unvaccinated patients with the same condition, new research suggests. The study found vaccinated patients were less likely to stay on dialysis after discharge,
Health officials are tracking a highly contagious new COVID-19 variant. This comes as confusion grows over vaccine recommendations moving forward.
Key Takeaways BioNTech is buying fellow German firm CureVac for approximately $1.25 billion as the COVID-19 vaccine maker moves to expand into cancer treatments.For each CureVac share they own, investors will get about $5.